Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Drug Plans Decoded: Biosimilars Part 1

The Pharmacy Consulting Team at Telus Health has published a good primer for private health insurers on biosimilars and the biosimilar landscape in Canada. First in series. 

Read more

Alberta adds Humalog insulin lisper to biosimilar switching program

Effective August 1, adult patients covered by Alberta’s public drug plan who take Humalog insulin lispro will be required to switch to a biosimilar version by February 1, 2022. All new patient starts for insulin lispro will be covered for the biosimilar.

Read more

New Brunswick adds Lovenox enoxaparin to biosimilar switching program

New Brunswick has expanded its biosimilar switching program. Patients who take Lovenox enoxaparin will need to switch to an enoxaparin biosimilar by Feb 28, 2022. New patient starts for enoxaparin will also be covered for a biosimilar.

Read more